Drugs / NDV-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01926028 | Jul 2013 → May 2015 | vulvovaginal candidiasis | NovaDigm Therapeutics, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01447407 Comparator | Sep 2011 → Mar 2012 | candidiasis, staphylococcal infection | NovaDigm Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01273922 Comparator | Jan → Oct 2011 | candidiasis, staphylococcal infection | NovaDigm Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NDV-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01273922 ↗ |
| Modality | Vaccine | “NDV-3, a Recombinant Alum-Adjuvanted Vaccine for Staphylococcus Aureus and Candida Infections” NCT01273922 ↗ |
| Route | Intramuscular | “All injections will be administered intramuscularly.” NCT01273922 ↗ |